Journal of Bone and Mineral Metabolism

, Volume 29, Issue 5, pp 582–587 | Cite as

Lack of bone metabolism side effects after 3 years of nasal topical steroids in children with allergic rhinitis

  • Ozkaya EminEmail author
  • Mete Fatih
  • Dibek Emre
  • Samanci Nedim
Original Article


This study evaluated the effects on bone mineral status of long-term treatment with intranasal budesonide (INB) spray, using the recommended dose, in pediatric patients with allergic rhinitis (AR). This retrospective, case–control study of 230 prepubertal children with perennial AR, who had used nasal budesonide at a mean daily dose of 100 μg (range, 89–132 μg) for at least 3 years intermittently, was conducted from May 2007 through May 2010. The bone mineral density (BMD) of the lumbar spine was measured by dual-energy X-ray absorptiometry. Levels of serum calcium, phosphorus, alkaline phosphatase (ALP), parathyroid hormone, and osteocalcin were also assessed. The results were compared to sex- and age-matched controls (n = 140), who were newly diagnosed children with AR without any corticosteroid treatment. The 230 study patients (145 boys) were aged from 7 to 11 years. The average age (± SEM) was 8.7 ± 0.7 years; the mean (± SEM) steroid dosage used was 73.5 ± 7.0 μg daily, with 65.2 ± 5.2 g total steroid use during treatment. The 140 control patients (90 boys) were aged from 6 to 11 years. No significant differences were observed in BMD (P > 0.05) between the study and the control groups. Although mean serum ALP level was higher, and cortisol, phosphorus, and osteocalcin levels were lower, in the treatment group, these differences were not statistically significant. The findings suggest that long-term intermittent treatment for 3 years with INB spray, 50 μg twice daily, for children with perennial rhinitis revealed no negative effect on BMD and associated parameters.


Intranasal budesonide Bone mineral density Allergic rhinitis Children 



The authors have no financial or personal relationships with other persons or organizations that could pose a conflict of interest in connection with the present work.


  1. 1.
    Skoner DP (2001) Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol 108:S2–S8PubMedCrossRefGoogle Scholar
  2. 2.
    Ibiapina Cda C, Sarinho ES, Camargos PA, Andrade CR, Cruz Filho AA (2008) Allergic rhinitis: epidemiological aspects, diagnosis and treatment. J Bras Pneumol 34:230–240PubMedGoogle Scholar
  3. 3.
    Bloebaum R (2002) Managing allergic rhinitis: the role of pharmacotherapy; sound treatment can improve your patient’s quality of life. J Respir Dis 23:370–376Google Scholar
  4. 4.
    Blaiss MS (2007) Safety consideration of intranasal corticosteroids for the treatment of allergic rhinitis. Allergy Asthma Proc 28:145–152PubMedCrossRefGoogle Scholar
  5. 5.
    Baena-Cagnani CE (2004) Safety and tolerability of treatments for allergic rhinitis in children. Drug Saf 27:883–898PubMedCrossRefGoogle Scholar
  6. 6.
    Rizzo MC, Solé D, Naspitz CK (2007) Corticosteroids (inhaled and/or intranasal) in the treatment of respiratory allergy in children: safety vs. efficacy. Allergol Immunopathol (Madr) 35:197–208CrossRefGoogle Scholar
  7. 7.
    Ebeling PR, Erbas B, Hopper JL, Wark JD, Rubinfeld AR (1998) Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J Bone Miner Res 13:1283–1289PubMedCrossRefGoogle Scholar
  8. 8.
    Jones A, Fay JK, Burr M et al (2002) Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease. Cochrane Database Syst Rev 1:CD003537Google Scholar
  9. 9.
    Altintas DU, Karakoc GB, Can S, Yilmaz M, Kendirli SG (2005) The effects of long term use of inhaled corticosteroids on linear growth, adrenal function and bone mineral density in children. Allergol Immunopathol 33:204–209CrossRefGoogle Scholar
  10. 10.
    Skoner DP, Rachelefsky GS, Meltzer EO et al (2000) Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 105:E23PubMedCrossRefGoogle Scholar
  11. 11.
    Schenkel EJ, Skoner DP, Bronsky EA, Miller SD, Pearlman DS, Rooklin A et al (2000) Absence of growth retardation in children with perennial allergic rhinitis after one-year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 105:E22PubMedCrossRefGoogle Scholar
  12. 12.
    Murph K, Uryniak T, Simpson B, O’Dowd L (2006) Growth velocity in children with perennial allergic rhinitis treated with budesonide aqueous nasal spray. Ann Allergy Asthma Immunol 96:723–730CrossRefGoogle Scholar
  13. 13.
    Möller C, Ahlström H, Henricson KÅ, Malmqvist LÅ, Åkerlund A, Hildebrand H (2003) Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 33:816–822PubMedCrossRefGoogle Scholar
  14. 14.
    Brozek JL, Baena-Cagnani CE, Bonini S et al (2008) Methodology for development of the Allergic Rhinitis and Its Impact on Asthma Guideline 2008 update. Allergy 63:38–46PubMedCrossRefGoogle Scholar
  15. 15.
    Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J et al (1999) Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 10:259–264PubMedCrossRefGoogle Scholar
  16. 16.
    Baim S, Leonard MB, Bianchi ML, Hans DB, Kalkwarf HJ, Langman CB, Rauch F (2008) Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom Assess Skelet Health 11:6–21CrossRefGoogle Scholar
  17. 17.
    Passalacqua G, Albano M, Canonica GW et al (2000) Inhaled and nasal corticosteroids: safety aspects. Allergy 55:16–33PubMedCrossRefGoogle Scholar
  18. 18.
    Juniper EF, Stahl E, Doty RL et al (2005) Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol 115:S390–S413PubMedCrossRefGoogle Scholar
  19. 19.
    Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Prestwood K, Frieri M et al (2005) Use of oral corticosteroids and risk of features. J Bone Miner Res 20:1487–1494PubMedGoogle Scholar
  20. 20.
    Bielory L, Blaiss M, Fineman SM, Ledford DK, Lieberman P, Simons FE et al (2006) Concerns about intranasal corticosteroids for over-the-counter use: position statement of the Joint Task Force for the American Academy of Allergy, Asthma and immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 96:1–12CrossRefGoogle Scholar
  21. 21.
    Martinati LC, Bertoldo F, Gasperi E, Fortunati P, Lo Cascio V, Boner AL (1998) Longitudinal evaluation of bone mass in asthmatic children with inhaled beclomethasone dipropionate or cromolyn sodium. Allergy 53:705–708PubMedCrossRefGoogle Scholar
  22. 22.
    Mainz JG, Sauner D, Malich A, John S, Beyermann H, Mentzel HJ et al (2008) Cross-sectional study on bone density related sonographic parameters in children with asthma: correlation to therapy with inhaled corticosteroids and disease severity. J Bone Miner Metab 26:485–492PubMedGoogle Scholar
  23. 23.
    Allen HD, Thong IG, Clifton-Blight P, Holmes S, Nery L, Wilson KB (2000) Effects of high-dose inhaled corticosteroids on bone metabolism in prepubertal children with asthma. Pediatr Pulmonol 29:188–193PubMedCrossRefGoogle Scholar
  24. 24.
    Wilson AM, Sims EJ, Mc Farlane LC, Lipworth BJ (1998) Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic-rhinitis. J Allergy Clin Immunol 102:598–604PubMedCrossRefGoogle Scholar
  25. 25.
    Sheth K (2008) Evaulating the safety of intranasal steroids in the treatment of allergic rhinitis. Allergy Asthma Clini Immunol 4:125–129CrossRefGoogle Scholar
  26. 26.
    Akil I, Yuksel H, Urk V, Onur E, Var A, Guvenc Y (2003) Biochemical markers of bone metabolism and renal calcium excreation in the asthmatic patient treated with inhaled corticosteroids. Asthma Allergy Immunol (Turkish) 1:5–10Google Scholar
  27. 27.
    Reilly SM, Hambleton G, Adams JE, Mughal MZ (2001) Bone density in asthmatic children terated with inhaled corticosteroids. Arch Dis Child 84:183–187PubMedCrossRefGoogle Scholar
  28. 28.
    Jones CD, Laval-Jeantet AM, Laval-Jeantet MH, Genant HK (1987) Importance of measurement of spongious vertabral bone mineral density in the assessment of osteoporosis. Bone (NY) 8:201–206Google Scholar
  29. 29.
    Kemp JP, Osur S, Shrewsbury SB, Herje NE, Duke SP, Harding SM et al (2004) Potential effect of fluticasone propionate on bone mineral density in patients with asthma; a 2-year randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 79:458–466PubMedCrossRefGoogle Scholar
  30. 30.
    Agertoft L, Pedersen S (1998) Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide. Am J Respir Crit Care 157:178–183Google Scholar
  31. 31.
    Johnston CC, Miller JZ, Slemenda CW (1992) Calcium supplementation and increase in bone mineral density in children. N Engl J Med 327:82–87PubMedCrossRefGoogle Scholar
  32. 32.
    Gagnon L, Boulet LP, Brown J, Desrosiers T (1997) Influence of inhaled corticosteroids and dietary intake on bone density and metabolism in patients with moderate to severe asthma. J Am Diet Assoc 97:1401–1406PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer 2011

Authors and Affiliations

  • Ozkaya Emin
    • 1
    Email author
  • Mete Fatih
    • 2
  • Dibek Emre
    • 3
  • Samanci Nedim
    • 4
  1. 1.Division Pediatric Allergy, Department of PediatricsBezmialem Vakif University Medical FacultyIstanbulTurkey
  2. 2.Department of Pediatrics70. Yıl Physical Therapy CenterIstanbulTurkey
  3. 3.Doganhisar Government HospitalKonyaTurkey
  4. 4.Department of PediatricsSuleymaniye Women and Child HospitalIstanbulTurkey

Personalised recommendations